Steven Cohen Beam Therapeutics Inc. Call Options Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding BEAM
# of Institutions
260Shares Held
93.6MCall Options Held
425KPut Options Held
309K-
Farallon Capital Management LLC San Francisco, CA9.93MShares$171 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.87MShares$153 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.48MShares$146 Million1.79% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$132 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$78.3 Million72.77% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.21B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...